Moreover, the KEYNOTE‐024 and KEYNOTE‐042 trials revealed that NSCLC patients with programmed cell death ligand‐1(PD‐L1) tumor proportion score (TPS) ≥50% who were treated with first‐line pembrolizumab monotherapy had a longer median OS than those treated with first‐line platinum‐based chemotherapy.5, 6. This evidence concerns the gene CD274 and non-small cell lung carcinoma.